← Back to Jubilant Pharmova Ltd. overview
Jubilant Pharmova Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹7,192 cr | ₹839 cr | ₹52.85 | ₹12,756 cr | ₹6,255 cr | 13.42% | 13.37% | 0.44x | 11.67% |
| FY2024 | ₹6,645 cr | ₹77 cr | ₹4.86 | ₹11,549 cr | ₹5,434 cr | 1.42% | 4.69% | 0.67x | 1.16% |
| FY2023 | ₹6,219 cr | ₹-61 cr | ₹-3.83 | ₹11,157 cr | ₹5,399 cr | -1.13% | 2.16% | 0.68x | -0.98% |
| FY2022 | ₹6,059 cr | ₹414 cr | ₹26 | ₹9,991 cr | ₹5,319 cr | 7.78% | 9.03% | 0.6x | 6.83% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.